English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Advanced Glycation End Products (AGEs), together with its receptor (RAGE) are known to play a predominant role in the onset of diabetic micro- and macrovascular diseases. Therefore, therapeutic interventions which can target AGE-RAGE axis are of great interest in diabetic therapy. Animal studies demonstrated promising results for most of the AGE-RAGE inhibitors but their actual clinical values are not fully elaborated.

Therapeutic Agents Targeting at AGE-RAGE Axis for the Treatment of Diabetes and Cardiovascular Disease: A Review of Clinical Evidence